Alagille syndrome is a genetic condition that affects the bile ducts in the liver and causes problems in several other organ systems, including the heart, skeleton, eyes, and face. It occurs in roughly 1 in 70,000 newborns, though the true number may be higher because some people never develop noticeable liver disease in infancy. The condition is present from birth and varies widely in severity, even among members of the same family.
How Alagille Syndrome Affects the Liver
The hallmark of Alagille syndrome is a shortage of bile ducts inside the liver. Normally, a network of tiny ducts carries bile from the liver into the intestine, where it helps digest fats. In Alagille syndrome, fewer of these ducts develop, so bile backs up in the liver. This backup is called cholestasis, and it produces the most recognizable early symptom: jaundice, or yellowing of the skin and eyes, usually noticed in the first few months of life.
Backed-up bile also causes intense itching (pruritus), which can be severe enough to disrupt sleep and daily life. Over time, children may develop yellowish fatty deposits under the skin called xanthomas, and their growth can fall behind. Up to 15% of people with Alagille syndrome progress to end-stage liver disease, which ultimately requires a transplant.
The Genetic Cause
Alagille syndrome follows an autosomal dominant inheritance pattern, meaning a single copy of a faulty gene from either parent is enough to cause it. In a large 27-year study of over 400 patients, about 94% had a mutation in the JAG1 gene, roughly 2.5% had a mutation in the NOTCH2 gene, and about 3% had no identifiable mutation in either gene. Both genes are part of a signaling pathway that guides how cells develop during early life, particularly in the liver, heart, and skeleton.
Many cases are sporadic, meaning the mutation appeared for the first time in the child rather than being passed down. If a parent does carry the mutation, each pregnancy has a 50% chance of passing it on, but the severity can differ dramatically between parent and child.
Heart and Blood Vessel Problems
Heart defects show up in nearly 88% of people with Alagille syndrome. The most common is narrowing of the pulmonary arteries, the blood vessels that carry blood from the heart to the lungs. Among those with heart involvement, pulmonary artery stenosis accounts for the vast majority of cases, with peripheral (branch) narrowing being the most frequent type.
Some children have more complex structural heart defects. In one pooled analysis, about 46% of patients with cardiac involvement had tetralogy of Fallot, a combination of four heart abnormalities that often requires surgical repair. Narrowing of the abdominal aorta and holes between heart chambers (atrial or ventricular septal defects) occur less commonly. Because of this range, cardiac evaluation is a standard part of the diagnostic workup.
Skeletal, Facial, and Eye Features
A distinctive finding on chest X-rays is the “butterfly vertebra,” where the bones of the spine have an unusual shape resembling butterfly wings. This happens because the two halves of the vertebral body don’t fully fuse during development. Butterfly vertebrae rarely cause back pain or structural problems on their own, but they’re a useful clue for diagnosis.
Children with Alagille syndrome often share a recognizable set of facial features: a triangular face with a broad forehead and pointed chin, a bulbous tip of the nose, deep-set eyes, and widely spaced eyes. These features become more noticeable with age and can help clinicians spot the syndrome even before genetic testing.
The most common eye finding is posterior embryotoxon, an extra circular line visible on the surface of the eye during a specialized exam. About 90% of children with Alagille syndrome have it, compared to 8 to 15% of the general population. It doesn’t affect vision and doesn’t need treatment, but its high prevalence in Alagille syndrome makes it diagnostically helpful.
How Alagille Syndrome Is Diagnosed
A clinical diagnosis requires bile duct paucity on liver biopsy plus at least three of five major features:
- Cholestasis (bile flow problems causing jaundice and itching)
- Congenital heart defect (most often pulmonary artery stenosis)
- Butterfly vertebrae (visible on X-ray)
- Eye abnormality (usually posterior embryotoxon)
- Characteristic facial features (triangular face, broad forehead, pointed chin)
If there’s a family history of the syndrome, only one of those five features plus bile duct paucity is needed. Genetic testing for JAG1 and NOTCH2 mutations can confirm the diagnosis and is especially useful in milder cases where not all clinical features are obvious.
Nutritional Challenges
Because bile is essential for absorbing dietary fat, children with Alagille syndrome often struggle to absorb fat-soluble vitamins: A, D, E, and K. Each deficiency carries its own risks. Low vitamin K increases bleeding risk, and intracranial bleeds have been reported. Vitamin A deficiency can lead to corneal damage and vision loss. Vitamin D deficiency weakens bones, and vitamin E deficiency can affect nerve function.
Supplementation of all four fat-soluble vitamins is a routine part of management, with doses adjusted based on blood levels and the severity of cholestasis. Water-soluble vitamins are typically given at twice the standard recommended amount. Specialized formulas with fats that are easier to absorb (medium-chain triglycerides) help infants and young children gain weight and grow.
Treatment and Medications
There is no cure for Alagille syndrome, so treatment focuses on managing symptoms and preventing complications. For the intense itching caused by bile acid buildup, a newer class of medications called ileal bile acid transporter inhibitors (including maralixibat) works by blocking the reabsorption of bile acids in the gut, allowing more to leave the body through stool. Multiple clinical trials have shown these drugs reduce both bile acid levels and itching severity in a significant portion of patients, though the response varies from person to person. Dosing often needs to be personalized rather than following a fixed schedule.
Heart defects are managed on a case-by-case basis. Mild pulmonary artery narrowing may only need monitoring, while more complex defects like tetralogy of Fallot typically require surgical correction.
Liver Transplantation
Liver transplantation becomes necessary when the disease progresses to liver failure, severe portal hypertension with dangerous bleeding, or fluid buildup in the abdomen that doesn’t respond to other treatment. Sometimes the decision is driven less by lab numbers and more by quality of life: a child whose growth has stalled or whose itching is unmanageable may be referred for transplant even before outright liver failure.
In one multicenter study of children with Alagille-related liver disease, the estimated transplant-free survival at age 18.5 years was just 24%, meaning fewer than one in four reached adulthood with their original liver. That statistic reflects the subset with significant liver involvement, not every person with the diagnosis. Many individuals with milder forms live with manageable symptoms and never need a transplant. Liver complications are thought to directly cause death in about 5% of patients overall.
Living With Alagille Syndrome
The variability of Alagille syndrome is one of its defining characteristics. Some children are diagnosed as newborns with severe jaundice and heart defects requiring early intervention. Others carry the same genetic mutation and are identified only as adults, sometimes after a child of theirs is diagnosed. Within a single family, one person may need a liver transplant while a sibling with the same mutation has little more than a heart murmur and mild facial features.
Ongoing care typically involves a team of specialists: a liver doctor (hepatologist), cardiologist, ophthalmologist, nutritionist, and sometimes a nephrologist, since kidney problems can also occur. Regular monitoring of liver function, growth, vitamin levels, and cardiac status helps catch complications early. Children who receive liver transplants generally do well long term, though they require lifelong immune-suppressing medication and monitoring for bone health, since vitamin D deficiency and post-transplant medications both contribute to fracture risk.